Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms (2015)

  • Authors:
  • USP affiliated authors: SANTOS, JOSE EDUARDO TANUS DOS - FMRP ; CAVALLI, RICARDO DE CARVALHO - FMRP
  • USP Schools: FMRP; FMRP
  • DOI: 10.1007/s00404-014-3475-2
  • Subjects: ENDOTÉLIO VASCULAR; POLIMORFISMO; PRÉ-ECLÂMPSIA
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s00404-014-3475-2 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Versões disponíveis em Acesso Aberto do: 10.1007/s00404-014-3475-2 (Fonte: Unpaywall API)

    Título do periódico: Archives of Gynecology and Obstetrics

    ISSN: 0932-0067,1432-0711



      Não possui versão em Acesso aberto
    Informações sobre o Citescore
  • Título: Archives of Gynecology and Obstetrics

    ISSN: 0932-0067

    Citescore - 2017: 1.97

    SJR - 2017: 0.956

    SNIP - 2017: 1.025


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FMRP2687997pcd 2687997 Estantes Deslizantes
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SANDRIM, Valeria C.; PALEI, Ana C. T.; ELEUTERIO, Nibia; TANUS-SANTOS, José Eduardo; CAVALLI, Ricardo de Carvalho. Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms. Archives of Gynecology and Obstetrics, Heidelberg, v. 291, n. 4, p. 799-803, 2015. Disponível em: < http://dx.doi.org/10.1007/s00404-014-3475-2 > DOI: 10.1007/s00404-014-3475-2.
    • APA

      Sandrim, V. C., Palei, A. C. T., Eleuterio, N., Tanus-Santos, J. E., & Cavalli, R. de C. (2015). Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms. Archives of Gynecology and Obstetrics, 291( 4), 799-803. doi:10.1007/s00404-014-3475-2
    • NLM

      Sandrim VC, Palei ACT, Eleuterio N, Tanus-Santos JE, Cavalli R de C. Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms [Internet]. Archives of Gynecology and Obstetrics. 2015 ; 291( 4): 799-803.Available from: http://dx.doi.org/10.1007/s00404-014-3475-2
    • Vancouver

      Sandrim VC, Palei ACT, Eleuterio N, Tanus-Santos JE, Cavalli R de C. Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms [Internet]. Archives of Gynecology and Obstetrics. 2015 ; 291( 4): 799-803.Available from: http://dx.doi.org/10.1007/s00404-014-3475-2

    Referências citadas na obra
    Ahmad S, Ahmed A (2004) Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95:884–891
    Anonymous (2000) Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 183:S1–S22
    Awata T, Inoue K, Kurihara S et al (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635–1639
    Chaiworapongsa T, Romero R, Kim YM et al (2005) Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 17:3–18
    Crawford DC, Nickerson DA (2005) Definition and clinical importance of haplotypes. Annu Rev Med 56:303–320
    de Vasconcelos D, Izidoro-Toledo TC, Sandrim VC et al (2009) Aldosterone synthase gene polymorphism is not associated with gestational hypertension or preeclampsia. Clin Chim Acta 400:139–141
    Demir R, Kayisli UA, Cayli S et al (2006) Sequential steps during vasculogenesis and angiogenesis in the very early human placenta. Placenta 27:535–539
    Demir R, Kayisli UA, Seval Y et al (2004) Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta 25:560–572
    Demir R, Seval Y, Huppertz B (2007) Vasculogenesis and angiogenesis in the early human placenta. Acta Histochem 109:257–265
    Esser S, Wolburg K, Wolburg H et al (1998) Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140:947–959
    Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676
    Girnita DM, Webber SA, Ferrell R et al (2006) Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation 82:1774–1780
    He H, Venema VJ, Gu X et al (1999) Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 274:25130–25135
    He Y, Smith SK, Day KA et al (1999) Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 13:537–545
    Jacobs EJ, Feigelson HS, Bain EB et al (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8:R22
    Johnson GC, Esposito L, Barratt BJ et al (2001) Haplotype tagging for the identification of common disease genes. Nat Genet 29:233–237
    Kendall RL, Thomas KA (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705–10709
    Kendall RL, Wang G, Thomas KA (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226:324–328
    Kroll J, Waltenberger J (1998) VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 252:743–746
    Lambrechts D, Storkebaum E, Morimoto M et al (2003) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34:383–394
    Maynard SE, Min JY, Merchan J et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658
    Podymow T, August P (2008) Update on the use of antihypertensive drugs in pregnancy. Hypertension 51:960–969
    Prior SJ, Hagberg JM, Paton CM et al (2006) DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. Am J Physiol Heart Circ Physiol 290:H1848–H1855
    Roberts JM, Gammill HS (2005) Preeclampsia: recent insights. Hypertension 46:1243–1249
    Sandrim VC, Coelho EB, Nobre F et al (2006) Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. Atherosclerosis 186:428–432
    Sandrim VC, de Syllos RWC, Lisboa HR et al (2006) Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus. Atherosclerosis 189:241–246
    Sandrim VC, Palei AC, Cavalli RC et al (2009) Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. Mol Hum Reprod 15:115–120
    Sandrim VC, Palei AC, Luizon MR et al (2010) eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J 10(1):40–45
    Sandrim VC, Yugar-Toledo JC, Desta Z et al (2006) Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy. J Hypertens 24:2393–2397
    Schneider BP, Radovich M, Sledge GW et al (2007) Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 20:20
    Shahbazi M, Fryer AA, Pravica V et al (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13:260–264
    Shen BQ, Lee DY, Zioncheck TF (1999) Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 274:33057–33063
    Shibuya M (2001) Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26:25–35
    Sibai BM (2008) Intergenerational Factors. A Missing Link for Preeclampsia, Fetal Growth Restriction, and Cardiovascular Disease? Hypertension 7:7
    Sibai BM, Barton JR (2007) Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol 196:514
    Smith GC, Crossley JA, Aitken DA et al (2007) Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 109:1316–1324
    Venkatesha S, Toporsian M, Lam C et al (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642–649
    Walker JJ (2000) Pre-eclampsia. Lancet 356:1260–1265
    Zachary I (2001) Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280:C1375–C1386
    Zhou Y, McMaster M, Woo K et al (2002) Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160:1405–1423